GE HealthCare Announces Phase I Results for a First-of-Its-Kind Macrocyclic Manganese-Based MRI Contrast Agent
October 09, 2024
October 09, 2024
CHICAGO, Illinois, Oct. 9 (TNSres) -- G.E. HealthCare issued the following news release:
* * *
* Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well tolerated with no serious adverse events, dose-limiting toxicities or clinically relevant findings reported.
* If approved, this agent could provide an alternative to gad . . .
* * *
* Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well tolerated with no serious adverse events, dose-limiting toxicities or clinically relevant findings reported.
* If approved, this agent could provide an alternative to gad . . .